Caplin Point Laboratories’ injectables facility completes INVIMA audit successfully

This is also an important milestone in our product strategy for our expansion into the larger Latin American market

INVIMA-Colombia has successfully concluded its inspection of Caplin Point Laboratories' Puducherry injectables plant (Dec 8-12, 2025). This achievement underscores the company's dedication to delivering affordable, quality healthcare and significantly strengthens our presence in the Latin American market."

Commenting on the completion of the inspection, C.C.Paarthipan, Chairman, said: "The successful completion of INVIMA inspection at our injectables facility in Puducherry reinforces our commitment to expanding our reach in Latin America and delivering high-quality, affordable medicines to the patient population in this region. This is also an important milestone in our product strategy for our expansion into the larger Latin American market for specialty injectable products. It complements our already INVIMA approved Softgel section at the same site."